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Decreased expression of caveolin-1 in Systemic Sclerosis: crucial
role in the pathogenesis of tissue fibrosis
Francesco Del Galdo, MD, PhD1, Federica Sotgia, PhD2, Cecilia de Almeida, PhD2, JeanFrancois Jasmin, PhD2, Megan Musick, BS1, Michael Lisanti, MD, PhD2, and Sergio A.
Jimenez, MD1
1Jefferson Institute of Molecular Medicine, Thomas Jefferson University, 233 s 10 th street, 19107
Philadelphia-PA
2Kimmel

Cancer Center, Thomas Jefferson University, 233 s 10th street, 19107 Philadelphia-PA

Abstract
Purpose—Recent studies have implicated caveolin-1 (cav-1), in the regulation of transforming
growth factor-β (TGF-β) downstream signaling. Given the crucial role of TGF-β in the pathogenesis
of Systemic Sclerosis (SSc) we examined here whether cav-1 is also involved in the pathogenesis of
tissue fibrosis in SSc. We analyzed the expression of cav-1 in affected SSc tissues, studied the effects
of lack of expression of cav-1 in vitro and in vivo, and analyzed the effects of restoration of cav-1
function on the fibrotic phenotype of SSc fibroblasts in vitro.
Methods—Cav-1 expression in tissues was analyzed by immunofluorescence and confocal
microscopy. Extent of tissue fibrosis in cav-1 knockout mice was assessed by histology/
histochemistry and quantified by hydroxyproline assays. Cav-1 null and SSc fibroblast phenotype
and protein production were analyzed by real time PCR, immunofluorescence, Western blots and
Multiplexed ELISA. The effects of cav-1 function restoration in SSc fibroblasts in vitro were also
examined employing a cell permeable recombinant cav-1 peptide.
Results—Cav-1 is markedly decreased in affected lungs and skin from SSc patients. Cav-1
knockout mice develop pulmonary and skin fibrosis. Cav-1 downregulation is maintained in cultured
SSc fibroblasts and restoration of cav-1 function in vitro normalizes their phenotype and abrogates
TGF-β stimulation through inhibition of Smad3 activation.
Conclusions—Caveolin-1 appears to participate in the pathogenesis of tissue fibrosis in SSc.
Restoration of cav-1 function by treatment with a cell permeable peptide corresponding to the cav-1
scaffolding domain may be a novel therapeutic approach in SSc.

Introduction
Systemic sclerosis (SSc) is characterized by excessive deposition of collagen and other
connective tissue macromolecules in skin and multiple internal organs, prominent and often
severe alterations in the microvasculature, and humoral and cellular immunologic
abnormalities (1). The excessive collagen deposition in SSc is due to overproduction of this
protein by fibroblasts (2-4). Indeed, it is the persistent activation of the genes encoding various
collagens in SSc fibroblasts that distinguishes controlled repair, such as that occurring during
normal wound healing, from the uncontrolled fibrosis that is the hallmark of SSc (5). Numerous
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alterations in the expression of cytokines and growth factors with potent effects on fibroblast
collagen synthesis, various endothelial cell functions, and T cell responses have been
demonstrated in SSc (6-8). Transforming growth factor β (TGF-β) is a growth factor that plays
a crucial role in tissue fibrosis (9-12) and it has been implicated in the pathogenesis of SSc
(1,12-17). An important effect of TGF-β is the stimulation of the expression of genes encoding
various collagens and other matrix proteins and the processing and tissue deposition of
interstitial collagens (9-11). Although SSc fibroblasts display increased TGF-β signaling (18,
19), the mechanisms responsible are not completely known. A recent study confirmed the
importance of the increased TGF-β pathway activation in SSc pathogenesis. In this study the
conditional, fibroblast-specific gene expression of a constitutively active TGF-β Receptor-1
(TGFβR-1) recapitulated the fibrotic process occurring in the skin, the vasculature and possibly
the lung of SSc patients (20).
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Caveolin 1 (cav-1) is the most important member of a family of membrane proteins that are
the major coating proteins of caveolae. Caveolae are 50- to 100-nm flask-shaped invaginations
which represent a morphologically identifiable subset of lipid rafts (21). The spatial
organization of cell receptors in lipid rafts can modulate the subsequent transmission of the
specific signal (22,23). Indeed, TGF-β 1 receptors are internalized both by cav-1 associated
lipid rafts and by early endosome antigen 1 non-lipid raft 1 pathways. Non-lipid raft associated
internalization increases TGF-β signaling, whereas, caveolin-associated internalization
increases TGF-β receptor degradation, thus, effectively decreasing or abolishing TGF-β
signaling (24,25). The increased TGF-β R-1 degradation is mediated by an interaction between
the receptor and the scaffolding domain of cav-1; the decreased availability of the activated
TGFβR-1 diminishes the phosphorylation of Smad2/3 and disrupts its interaction with Smad4
and its subsequent nuclear translocation (26).
The possible participation of cav-1 in the pathogenesis of fibrotic diseases was first suggested
by Tourkina et al. (27) who demonstrated that cav-1 knock-down in vitro resulted in a 5-fold
increase in COL1A2 gene expression by normal human lung fibroblasts, whereas, increased
cav-1 expression caused a reduction in collagen production. A recent study (28) described a
marked reduction of cav-1 expression in lung tissues and in lung fibroblasts from patients with
idiopathic pulmonary fibrosis compared to cells from normal lungs. These authors also
demonstrated that induction of cav-1 expression markedly ameliorated bleomycin-induced
pulmonary fibrosis and suppressed TGF-β1-induced stimulation of extracellular matrix
production in cultured fibroblasts.
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Based on these observations, we raised the question of whether cav-1 is involved in the
pathogenesis of tissue fibrosis in SSc. Here, we present evidence supporting the hypothesis
that cav-1 plays a role in the pathogenesis of tissue fibrosis in SSc. Furthermore, our results
suggest that an increase of cav-1 function employing a cell membrane permeable cav-1
scaffolding domain peptide may be a novel therapeutic approach to limit the progression of
tissue fibrosis in SSc.

Methods
Patients
Full thickness skin biopsies were surgically obtained from three patients with SSc of recent
onset (<18 months from the appearance of clinically detectable skin induration) and three
normal controls with IRB approval. The SSc patients satisfied the criteria for the classification
of SSc (29) and had the diffuse cutaneous clinical subset of the disease as defined by LeRoy
et al. (30). Skin biopsies were obtained from the leading edge of the lesion on the forearms.
The tissues remaining after diagnostic histopathology were used for fibroblast isolation and
for immunohistology. Paraffin embedded sections from surgical open lung biopsies from two
Arthritis Rheum. Author manuscript; available in PMC 2009 October 28.
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patients with SSc associated pulmonary fibrosis and from one autopsy from a patient with SSc
pulmonary hypertension were obtained. The histopathological examination of skin showed the
typical changes of SSc. The two lung biopsies displayed the typical features of non-specific
interstitial pneumonitis. The lungs from the autopsy case showed typical histopathological
findings of pulmonary arterial hypertension.
Animals and histopathology studies
Cav-1 deficient mice were generated as previously described are in the C57Bl/6 genetic
background (31). Six same gender mice per group were sacrificed at 3 months of age. After
hair removal with a commercial depilatory, full thickness skin samples were surgically excised
from the interscapular region of the animals, stretched and pinned in histopathology cassettes
and fixed in phosphate buffered formalin for 24 h. The lungs were removed and the left lung
was processed by perfusion of the left pulmonary artery with paraformaldehyde to attain
fixation of the parenchyma avoiding alveolar collapse or atelectasis as described previously
(32). The entire right lung was hydrolyzed and used for hydroxyproline assays. Paraffin
embedded skin and lungs were stained with hematoxylin/eosin and Masson's trichrome
according to standard procedures.
Hydroxyproline assays
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Confocal microscopy studies
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The collagen content in the lungs and skin of the same animals sacrificed for the histopathology
studies was determined by hydroxyproline assays. Skin samples obtained from an area adjacent
to that used for histopathology with a 4mm tissue punch, and the right lung were weighted and
hydrolyzed in 6M HCl overnight at 110°C for determination of their hydroxyproline content,
as described (33).

Cell culture

Cav-1 protein was analyzed by immunofluorescence using a anti-cav-1 rabbit polyclonal
antibody (Santa Cruz Biotechnology, Cambridge, MA). Rabbit IgG (Sigma, St Louis, MO)
was used as isotype control. For Smad localization studies, cells were fixed and permeabilized
as described (34). Anti Smad3 antibodies (Upstate, Temecula, CA) were used at a 1:200
dilution. Secondary antibodies used in the studies were affinity purified sheep FAB' anti rabbit
IgG conjugated with different fluorochromes (Sigma). Paraffin embedded sections from skin
and lung were processed as described (35). The primary antibody incubation step was
performed in a dark humidified chamber over-night at 4 °C and then incubated with the
secondary antibody (1:200). The unbound antibodies were removed from the section following
each incubation with 3 changes of PBS for 2 min each. Tissue sections or fixed cells were then
counterstained with DAPI and analyzed using a Zeiss LSM 510 META Confocal Laser
Scanning Microscope System and software. The two channels were recorded simultaneously
if no cross-talk could be detected. The breakthrough of the DAPI signal into the red and the
green channels was recorded separately and subtracted from the DAPI blue channel. Each
image was scanned 8 times to separate signal from noise. Panels were assembled using
Photoshop software without any RGB modification.

Fibroblasts from normal and SSc dermis were cultured in Dulbecco's Modified Eagle's Medium
(DMEM) supplemented with 10% FBS, antibiotics and glutamine (complete medium) until
confluent. Fibroblasts from cav-1 knockout or WT mice were obtained by subculturing full
thickness skin biopsies from age and sex matched animals. Both human and mouse fibroblasts
were used at passages 4 to 10.
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Fibroblasts were harvested with trypsin/EDTA, washed in PBS and then processed for RNA
extraction (RNAeasy kit; Quiagen, Valencia, CA) according to the manufacturer's protocol,
including a genomic DNA digestion step. Total RNA (2 μg) was reverse-transcribed using
Super-script-II reverse transcriptase (Invitrogen). Real-time PCR was performed using SYBR
green Master mix chemistry employing a standard amplification protocol on a Bio-Rad MyiQ
real-time PCR system (Bio-Rad, Hercules, CA). Reactions were conducted as described (36).
To confirm the amplification specificity, the PCR products were subjected to melting
temperature dissociation curve analysis. No amplification and no template controls were
examined in parallel. The differences in the number of mRNA copies in each PCR reaction
were corrected for endogenous control transcript levels; the control experiment levels were set
as 100 and all the other values expressed as a multiple thereof.
Primer sequences
All primers were designed using Primer Express (Applied Biosystem) and validated on NCBI
database for specificity (Table 1).
ELISA
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SearchLight® proteome arrays (Pierce Biotechnology, Woburn, MA) were performed to
measure the levels of IL-6 and MMP-3 in supernatants from mouse fibroblasts and the levels
of MMP-3 and PAI in tissue culture supernatants form human fibroblasts as described (36).
Briefly, samples were diluted 1:5, 1:50 or 1:1000 before a one h incubation on the array plates,
which had been pre-spotted with capture antibodies specific for each protein. Plates were
decanted and washed three times before adding a mixture of biotinylated detection antibodies
to each well. After incubating with detection antibodies for 30 min, plates were washed three
times and incubated for 30 min with streptavidin-horseradish peroxidase. Plates were again
washed before adding SuperSignal® Femto Chemiluminescent substrate. The plates were
immediately imaged using the SearchLight imaging system and data were analyzed using
ArrayVision software.
Western Blot analysis
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Intracellular proteins in whole cell lysates were obtained by lysing the confluent cells in 100
mm dishes as described (36). Fifty μg of protein were used per each sample. Primary antibodies
used in the different experiments were: cav-1 polyclonal rabbit antibody (Santa Cruz) at a
1:1000 dilution, collagen I polyclonal rabbit antibody (Rockland, Gilbertsville, PA) at a 1:3000
dilution in 5% milk TBST overnight at 4 °C; rabbit anti connective tissue growth factor (CTGF)
polyclonal antibodies (ABCAM, Cambridge, MA), and rabbit anti-phospho-Smad 2/3
polyclonal antibodies (Chemicon International, Temecula, CA). Anti rabbit HRP conjugated
antibodies at a 1:3000 dilution were used as secondary antibodies. To verify equal loading and
transfer the membranes employed for intracellular protein blots were stripped using Pierce
RESTORE™ stripping buffer and re-probed with rabbit anti human actin antibodies
(Rockland) at a 1:1000 dilution in 5% milk TBST overnight at 4 °C.
Treatment of cells with cell permeable peptides
It has been demonstrated that cav-1 regulates TGF-β/Smad signaling through an interaction
between the TGFR-1 receptor and a peptide corresponding to the scaffolding domain of cav-1
(DGIWKASFTTFTVTKYWFY) (26). Confluent cells between passages 4 and 9 were treated
for 24 h with either penetratin peptide, a 16-amino acid cell permeable peptide corresponding
to the homeodomain of the Drosophila transcription factor antennapedia
(RQPKIWFPNRRKPWKK) or with a peptide consisting of the fusion of the antennapedia
peptide and the peptide corresponding to the scaffolding domain of cav-1 (32). This fusion
Arthritis Rheum. Author manuscript; available in PMC 2009 October 28.
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peptide, referred to as cav-1p, was used at 2.5 and 5 μM final concentrations. Fibroblasts were
incubated in duplicate for each experiment for 24 h with or without 10 ng/ml TGF-β. Following
24 h incubation with or without TGF-β, one experimental plate was harvested and processed
for RNA extraction for real time PCR and the other was processed to obtain cell lysates for
Western blots. Tissue culture supernatants were collected to analyze collagen production by
Western blot.
Statistics
The resulting data were subjected to two-tailed t-test for statistical significance. A p value of
<0.05 was considered significant.

Results
Decreased levels of Cav-1 in affected SSc lung
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Affected tissues from patients with SSc-related pulmonary fibrosis and PAH displayed reduced
cav-1 immunofluorescence compared to normal lungs (Figure 1). The reduction in fluorescence
staining for cav-1 was observed in the thickened alveolar septa typical of SSc alveolitis (Figure
1B). This reduction was even more apparent in the neointima of pulmonary arteries in lungs
from SSc patients affected by PAH (Figure 1C) and in the interstitium of a lung section from
a region where the normal lung architecture has been replaced by fibrotic tissue (Figure 1D).
In contrast, intense cav-1 immunofluorescence was observed in histopathologically nonaffected areas of SSc lung tissues from the same patients (Figure 1E). Quantitative analysis of
the integrated density of fluorescence in three different fields per each type of lung involvement
represented in panels A-E was performed employing Image J software. The ratio between cav-1
immunofluorescence staining (green fluorescence) and the number of cells in the sample as
assessed by DAPI staining of their nuclei was 1.95 in normal lung and 2.1 in histopathologically
non-affected SSc lung biopsies, compared to 0.79 in the alveolitis sections, 0.60 in the PAH
sections, and 0.66 in the late fibrotic lesions sections. These data are shown in Figure 1F. Hence,
the three types of SSc lung involvement analyzed showed, respectively, 59%, 69% and 66%
decrease in relative cav-1 immunofluorescence levels compared to either normal lung tissue
or to histopathologically non-affected areas of SSc lung.
Cav-1 levels are decreased in SSc skin and in SSc dermal fibroblasts
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The expression of cav-1 observed by confocal microscopy was markedly reduced in SSc
affected skin (Figures 2A-D). We then compared by quantitative analysis of the integrated
density of fluorescence the levels of cav-1 in three normal and three SSc skin biopsies. The
results indicated that the cav-1/DAPI immunofluorescence ratio in the SSc affected skin was,
in average, less than 50% than that observed in normal skin (Figure 2E). To confirm these
results we studied in vitro cultured fibroblasts derived from SSc lesional skin because these
cells recapitulate the most important molecular alterations responsible for the fibrotic
phenotype observed in SSc skin in vivo. In these studies we compared the amount of cav-1
protein between SSc and normal dermal fibroblasts by immunofluorescence analysis (Figure
2F) and Western blot (Figure 2G). Both studies showed a dramatic decrease of cav-1 in SSc
dermal fibroblasts compared to normal dermal fibroblasts.
TGF-β downregulates cav-1 expression in vitro
To investigate whether the potent profibrotic growth factor, TGF-β may be involved in the
observed reduction of cav-1 in affected SSc tissues we examined the effects of TGF-β on cav-1
expression in cultured human normal dermal fibroblasts. As shown in Figures 2H, and 2I, we
observed a profound decrease in cav-1 mRNA and protein levels following 24 h incubation
with 10 ng/ml human recombinant TGF-β.

Arthritis Rheum. Author manuscript; available in PMC 2009 October 28.
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To investigate whether the observed reduction of cav-1 in affected SSc lung and skin biopsies
in vivo and in SSc cultured fibroblasts in vitro could play a role in the pathogenesis of tissue
fibrosis we analyzed by histopathology the skin and lungs of mice lacking cav-1 expression.
We observed that cav-1 null mice lungs had increased staining in the interstitium, indicating
an increase of the collagen content in the lungs. The histopathologic analysis of paraffin
embedded sections of skin biopsies from the same mice showed an increase in the thickness
of the dermis which was accompanied by an increase in collagen staining (Figure 3A).
Hydroxyproline assays on lung and skin from six 12-week old cav-1 knockout mice and six
matched wild type (WT) littermates showed that the collagen content of cav-1 null mice lungs
was 2.5 fold greater than that of WT animals (average cav-1 null = 0.86 μg/mg; WT = 0.35
μg/mg; p<0.001) and that skin of cav-1 null mice contained 2.4 fold more collagen that skin
from WT mice (average cav-1 null = 6.8 μg/mg; WT = 2.8 μg/mg; p=0.002) (Figure 3B).
Cav-1 null fibroblasts display a profibrotic phenotype in vitro
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To determine whether the skin fibroblasts obtained from cav-1 null mice recapitulate in vitro
the molecular events associated with a profibrotic phenotype, we examined collagen, α-smooth
muscle actin (α-SMA) and metalloproteinase (MMP) gene expression in cav-1 null fibroblasts
by real time PCR. We observed a 2-fold increase in col1a1 transcript levels, a 3.5 fold increase
in α-SMA expression and an 80% reduction in MMP-3 mRNA (Figure 3C). Furthermore, we
also found an increase in IL-6 and a reduction in mmp-3 protein levels, as determined by ELISA
of tissue culture supernatants (Figure 3D).
A cav-1 cell permeable peptide downregulates SSc fibroblast collagen production and
suppresses the upregulation of TGF-β inducible genes in vitro
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We next set out to examine whether cav-1p, a cell permeable cav-1 scaffolding domain peptide,
previously shown to be able to inhibit TGF-β pathway activation and to mimic cav-1 function
in a rat model of PAH (26,32), could exert an antifibrotic effect on SSc fibroblasts. We analyzed
the effects of the cav-1p on SSc fibroblasts either under control conditions or following
stimulation with TGF-β. We found that treatment of SSc dermal fibroblasts with cav-1p caused
a reduction in their collagen expression both at the basal level and following TGF-β stimulation
(Figure 4A). Furthermore, gene expression analysis of CTGF, a potent profibrotic TGF-β
inducible gene, showed that treatment with cav-1p reduced its basal level of expression and
abrogated the stimulation normally induced by TGF-β (Figure 4A). The results shown in Figure
4A were confirmed at the protein level for both proteins. Western blots for type I collagen
indicated that incubation with 2.5 or 5 μM cav-1p caused a profound reduction in basal collagen
production (Figure 4B). Furthermore, we also observed that 5 μM cav-1p abrogated TGF-β
induced type I collagen stimulation (Figure 4B). These effects were not caused by cellular
toxicity induced by the cav-1p as cell viability assays did not show any differences between
treated and untreated cells at 18 and 24 h time points (Figure 4C). Western blots for CTGF of
the cell lysates from SSc fibroblasts incubated with TGF-β for 24 or 48 h confirmed at the
protein level the inhibitory effects of 24h cav-1p treatment observed at the mRNA level (Figure
4D). PCR analysis and immunofluorescence studies of SSc fibroblasts indicated that the basal
expression of α-SMA transcripts and α-SMA containing stress fibers were reduced by treatment
with 10 μM cav-1p and that treatment with the peptide inhibited the TGF-β induced increased
levels of α-SMA mRNA and stress fibers (Figures 5A and 5B). The cav-1 peptide also reduced
the effects of TGF-β on the production of plasminogen activator inhibitor 1 (PAI1) and
increased the production of MMP-3 regardless of TGF-β stimulation, as demonstrated by
ELISA of the tissue culture supernatants (Figure 5C).
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A cav-1 cell permeable peptide inhibits TGF-β pathway activation through suppression of
Smad3 phosphorylation
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To gain a mechanistic insight in the observed inhibitory effects of the cav-1p on TGF-β pathway
activation, we analyzed Smad3 phosphorylation in SSc fibroblasts following TGF-β
stimulation. We observed that cav-1p inhibited the TGF-β induced phosphorylation of Smad3
as early as 5 min following TGF-β stimulation. The inhibition was more pronounced at 15, 30
and 60 min following TGF-β (Figure 6A). To examine whether cav-1p also reduced the
translocation of activated Smad3/4 complexes from the cytoplasm to the nucleus we analyzed
by immunofluorescence the cellular localization of Smad following incubation of SSc dermal
fibroblasts with TGF-β. We observed that the expected nuclear localization of Smad3 at 60
min following TGF-β stimulation was almost completely abrogated in the presence of 5 μM
cav-1p (Figure 6B).

Discussion
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Since the discovery of the potent profibrotic and immunomodulatory activities of TGF-β, this
growth factor has been recognized as one of the most important molecules in the pathogenesis
of SSc and other fibroproliferative diseases (1,9-20). The classic pathway of TGF-β signal
transduction involves the ligand-bound TβRII which recruits the TGF-βI receptor (TβRI) and
then transphosphorylates specific serine and threonine residues in a short (30 amino acid)
regulatory sequence known as the GS region (37,38). Signaling from the phosphorylated
TβRI receptor to the nucleus then occurs through the Smad family of proteins (39). Smad2 or
Smad3, two of the five receptor activated Smads (RSmads), bind to the activated TGF-β
receptor complex and become phosphorylated, allowing the formation of a complex with the
co-Smad, Smad4, a cytoplasmic protein which translocates the Smad complex through nuclear
membrane pores into the nucleus. Once in the nucleus, Smad3/Smad4 complexes act as
transcription factors, binding with the help of intranuclear transcriptional partners to specific
DNA binding sites in the promoter regions of target genes and activating their expression. To
further add to the complexity of the TGF-β activation and signaling cascades, it has been
recognized that there are numerous other non-Smad mediated events involved in TGF-β
functions and effects (40,41). Furthermore, it has also been recently demonstrated that other
non-TGF-β dependent pathways may be necessary for the expression of the full SSc fibroblast
phenotype. For example, Chen et al. (42) found that the overexpression of CTGF and α-SMA
in SSc fibroblasts was independent of TGF-β signaling, as it could not be abolished by treatment
of the cells with a specific inhibitor of ALK-5, the receptor involved in the canonical TGF-β
activation cascade.
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Another important mechanism of regulation of TGF-β activation involves the intracellular
degradation of the activated TGF-β receptor complex. The important role of cav-1 in this
regulation has recently been recognized (23-26) and it has been suggested that alterations in
this process may participate in the initiation and progression of tissue fibrosis (27,28). Thus,
the purpose of the present studies was to examine the role of cav-1 in the pathogenesis of tissue
fibrosis in SSc. We demonstrate here that the levels of cav-1 in affected SSc lung and skin
were substantially lower in comparison with normal tissues. Interestingly, our findings that
cav-1 expression was not reduced in histopathologically non-affected areas of SSc lungs
indicate that reduction of cav-1 expression may be a specific component of the actual pathologic
process rather than the result of a generalized manifestation of SSc. Additionally, our
observations that cav-1 is also low in lesional SSc skin indicates that regardless of the anatomic
site, a reduction in cav-1 likely represents a marker of the pathologic process in SSc.
To explore the functional effects of decreased cav-1 expression in vivo, we employed cav-1
knockout mice (31) and performed a detailed histopathologic analysis of skin and lung tissues
from these mice. In these studies we found that the lack of cav-1 expression was accompanied
Arthritis Rheum. Author manuscript; available in PMC 2009 October 28.
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by skin and lung fibrosis supporting the notion that the observed decreased expression of cav-1
in SSc tissues may participate in the fibrotic process rather than being only an epiphenomenon.
Furthermore, we found that cav-1 null fibroblasts displayed a profibrotic phenotype
characterized by an increased expression of type I collagen, α-SMA and IL-6 and decreased
production of MMP-3. In support of our observations are the results of a recent study (28)
which showed that induced overexpression of cav-1 in vitro employing an adenoviral vector
suppressed the expression of various genes encoding extracellular matrix molecules as well as
TGF-β induced α-SMA upregulation in the MRC-5 fibroblast line.
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To further examine the role of decreased cav-1 expression in the development of tissue fibrosis
we explored the effects of increasing cav-1 function in SSc fibroblasts on the expression of
genes encoding various key proteins participating in the process of pathologic fibrogenesis.
The numerous and potentially serious difficulties encountered with the clinical application of
virally-mediated gene therapy approaches (43-47) has stimulated the search for alternative
methods of delivery of therapeutic proteins into cells. One of the most promising approaches
is the utilization of novel cell permeable carriers capable of shuttling small peptides and
proteins inside cells (48). One such carrier which has been utilized extensively is the small
peptide, penetratin. Hence, we treated SSc fibroblasts in vitro with a cell permeable cav-1
scaffolding domain peptide (cav-1p), previously shown to be capable of increasing the
intracellular bioavailability of cav-1 (26,32), and examined whether the reconstitution of
intracellular cav-1 function resulted in a modulatory effect on the profibrotic phenotype of SSc
fibroblasts. We found that the administration of cav-1p in vitro to SSc fibroblasts caused a
significant reduction in the basal level of COL1A1 production, as well as a reduction in CTGF
protein levels and α-SMA containing stress fibers. Of further interest, was the observation that
the TGF-β induced upregulation of COL1A1, CTGF and α-SMA was strongly inhibited by
treatment of SSc cells with cav-1p. Subsequently, we demonstrated that the inhibitory effects
of cav-1p on TGF-β pathway activation were associated with the inhibition of Smad3
phosphorylation and of its nuclear translocation.
However, it should be noted that in the absence of TGF-β stimulation SSc fibroblasts did not
show appreciable nuclear accumulation of Smad3. Although these results are in contrast with
previously published data on Smad3 nuclear localization in SSc fibroblasts (19), they support
the participation of non-Smad3-mediated pathways in the activation of the SSc fibroblast
phenotype as suggested by Chen et al (42) and suggest that in the absence of exogenous TGFβ stimulation cav-1p could function in a TGF-β/Smad independent pathway.
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In summary, the studies described here support strongly the hypothesis that decreased
expression of cav-1 in SSc tissues plays a role in the development and progression of tissue
fibrosis by mediating a sustained activation of the TGF-β pathway. Furthermore, we
demonstrated that an in vitro intervention capable of increasing cav-1 function employing a
cell permeable cav-1 peptide, reverted the profibrotic phenotype of SSc fibroblasts in vitro an
that this effect was mediated by the suppression of the cascade of events induced by TGF-β
receptor ligation as shown by the abrogation of Smad3 phosphorylation and nuclear
translocation.
These results suggest that restoration of cav-1 function in vivo employing cell permeable cav-1
peptides may be effective to prevent the progression and limit the extension of tissue fibrosis
in SSc. Future studies should be performed to fully assess the long-term safety and effectiveness
of cav-1p administration in vivo as a novel therapeutic approach for SSc.
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Figure 1. Confocal microscopy imaging of cav-1 in SSc lung

A: Normal lung immunostained for cav-1. Note the homogeneous green staining for cav-1 on
the surface of each alveolar cell of the alveolar wall with an evident cell membrane pattern.
The nuclei of all cells are stained with DAPI and appear blue. B: SSc lung immunostained for
cav-1. Note that in contrast with A, there is non- homogeneous staining of cav-1 with markedly
reduced levels of immunofluorescence in the involved alveolar septa as indicated by numerous
cells (blue nuclei) without any detectable cav-1 staining in their surface. C: Pulmonary artery
in the lung form a patient affected by SSc-related pulmonary artery hypertension. Note the
reduced cav-1 immunofluorescent signal in most cells (blue nuclei) of the vessel wall. D: A
fibrotic area of a lung from a SSc patient. Note the absence of cav-1 staining in many stromal
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cells (arrows). The images of each panel are representative of tissue samples from three
different patients. E: Histopathologically non-affected area of lung from the same SSc patient
shown in panels B and D. F: Bar graph of the ratio between cav-1 and DAPI integrated density
of fluorescence (IDF) in panels A-E. (N=3; * = p<0.05 vs. A).
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Figure 2. A-D: Confocal microscopy imaging of cav-1 in SSc skin

Non specific auto fluorescence of the DAPI channel is shown to display skin anatomy of (A)
normal skin biopsy and (B) SSc skin biopsy. Note the tightly packed collagen fibrils in the
lower dermis of the SSc biopsy. C: Confocal microscopy of the same section shown in A
stained for cav-1 (green) and DAPI (Blue). Note the presence of intense cav-1 immunostaining
surrounding almost every cell in the dermis. D: Same section shown in B stained for cav-1
(green) and DAPI (blue). Note that most cells (blue nuclei) do not show any detectable cav-1
staining (green) in their surface. The images shown in each panel are representative of tissue
samples from three different patients. E: Quantitative analysis of fluorescence. Bar graph of
the ratio between cav-1 and DAPI integrated density of fluorescence (IDF) in panels C and D.
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(*= p<0.05). F-G: Cav-1 expression in SSc fibroblasts in vitro. F: Immunofluorescence
analysis of cav-1 expression (red) in confluent normal and SSc fibroblasts (both at passage 5).
The figure shows a representative result from experiments performed with two normal and two
SSc cell lines each in triplicate. Nuclei are stained with DAPI (Blue). G: Cell lysates from two
SSc dermal fibroblast cell lines and two normal dermal fibroblast cell lines were analyzed by
Western blot for cav-1. Antibodies directed against β-actin were used as control for equal
protein loading. H-I: Cav-1 expression following TGF-β stimulation. H: mRNA levels for
cav-1 were analyzed in two normal human fibroblast lines by real-time PCR following 24 h
incubation with 10ng/ml TGF-β. Each bar represents the average ± SD of three different PCR.
Cav-1 mRNA levels of the first line were arbitrarily set to 100 and all the other values calculated
as multiples thereof. ** = p<0.01. I: Cell lysates from the same two human dermal fibroblast
lines analyzed by Western blot for cav-1 following the same conditions described in panel H.
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Figure 3. A-B: Cav-1 knockout mice display increased collagen content in their lungs and skin
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A. Masson's Trichrome staining of collagen in the lung interstitium (upper panel) and in the
skin (lower panel) of wild type (WT) and cav-1-/- lung (CAV -/-) (upper panel: 400× lower
panel: 200×). B: Hydroxyproline assays of lungs from 6 cav-1-/- and 6 WT 12-week-old mice.
Each symbol (squares for WT and triangles for cav-1-/-) represents one animal. Results are
shown as μg of hydroxyproline /mg of wet weight of the tissue. Paired t-test analysis showed
p<0.001 for both. C-D: Cav-1-/- fibroblasts display a profibrotic phenotype. C: mRNA levels
for COL1a1, MMP-3 and α-SMA were analyzed by quantitative real time PCR in WT (white
bars) and cav-1-/- (black bars) fibroblasts. Each bar represents average ±SD of three different
PCR. The mRNA levels of the WT line were arbitrarily set to 100 and all the other values
calculated as multiples thereof. The transcript levels were corrected for 18S RNA levels. * =
p < 0.05; ** = p < 0.005. D: Tissue culture supernatants from confluent WT or cav-1-/fibroblasts were analyzed for IL-6 and MMP-3 by multiplex ELISA using Pierce Searchlight
Multiplexed Proteome Arrays. Culture media from three separate WT and cav-1-/- cell lines
were analyzed in duplicate; *** = p< 0.0001.
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Figure 4. Effects of cav-1p on SSc fibroblast profibrotic phenotype

A: Real time PCR analysis of COL1A1 and CTGF mRNA from SSc dermal fibroblasts treated
for 24 h with 10 ng/ml of human recombinant TGF-β in the presence of either 5 μM cav-1p
(cav-1p) or 5 μM control peptide (penetratin-AP). mRNA levels for each gene under control
conditions (penetratin without TGF-β) were set to 100. Other values were then calculated as a
multiple thereof. Bars represent the average of three different PCR reactions. The results shown
are representative of three different experiments. * = p<0.05; *** = p< 0.001. B: Western blot
for collagen I in tissue culture supernatants from SSc fibroblasts treated for 24 h with cav-1p
or penetratin alone (Control) with and without TGF-β. C: Cell viability of confluent dermal
fibroblast monolayers assessed by WST-1 assay following 18, 20 or 24 h treatment with cav-1p,
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or penetratin alone (CTRL). NS: Not statistically significant. D: Western blot for CTGF in cell
lysates from SSc fibroblasts following 24 h and 48 h TGF-β incubation in the presence of either
control peptides (-) or cav-1p (+).
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Figure 5.
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A: Real time PCR analysis of mRNA levels of α-SMA from SSc dermal fibroblasts treated for
24 h with 10 ng/ml of human recombinant TGF-β in the presence of either 5 μm cav-1p (cav-1p)
or 5 μm control peptide (penetratin-AP). mRNA levels for each gene under control conditions
(penetratin without TGF-β) were set to 100. Other values were then calculated as a multiple
thereof. Bars represent average of three different PCR reactions. The results shown are
representative of three different experiments. *** = p< 0.001. B: Immunofluorescence for αSMA in SSc cells in the same experimental conditions described in A. Note the decreased
number of fibroblasts expressing stress fibers in the presence of cav-1p both at basal level and
following TGF-β stimulation. Original magnification 200×. C: ELISA of tissue culture
supernatants for PAI and MMP-3. The results shown are the average of two different cell lines,
each assayed in duplicate at three different dilutions. * =p<0.05; ** p= 0.01.
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Figure 6.

A: Cell lysates from SSc fibroblasts prepared 5, 15, 30 and 60 min following TGF-β stimulation
(10ng/ml) in the presence or absence of cav-1 peptides were examined by Western blot using
an antibody specific for phosphorylated Smad2/3. To document equal loading and transfer, the
same membrane was stripped and reblotted with β-actin (β-ACT) antibodies B: Intracellular
immunolocalization of total Smad3 in SSc fibroblasts following 60 min incubation with cav-1p
or control peptide (CTRL) in the presence or not of TGF-β (10ng/ml). Note the marked nuclear
accumulation of Smad3 following TGF-β treatment and the almost complete abrogation of this
accumulation in cells treated with cav-1p. Original magnification 1000×.
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Oligonucleotides employed for Sybr-green quantitative RT-PCR
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HUMA
N
β -ACT TTGCCGACAGGATGCAGAA
COL1A1 CCTCAAGGGCTCCAACGAG
CAV-1 CGACCCTAAACACCTCAACGA
CTGF GTGTGCACTGCCAAAGATGGT
α-SMA TGTATGTGGCTATCCAGGCG
MOUSE
18S
GAAACGGCTACCACATCCAAGGA
A
col1a1 CTGGCCCAGGCAGTCAGAT
mmp3 GTGTGCACTGCCAAAGATGGT
α-SMA GTGGCCCCTGAAGAGCATC

GCCGATCCACACGGAGTACTT
TCAATCACTGTCTTGCCCCA
TCCCTTCTGGTTCTGTCA
TTGGAAGGACTCACCGCTG
AGAGTCCAGCACGATGCCAG
ACAATACAGGACTCTTTCGAGCCCTGTA
A
GGGTTTGCTACAACATGGGCTA
TTGGAAGGACTCACCGCTG
AATCTGGGTCATTTTCTCCCG
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